Meta-analysis of Chinese medicine in the treatment of adenoidal hypertrophy in children

Liu, Xiuxiu; Jiang, Zeming; Xiao, Zhen; Jiang, Yonghong; Li, Wen; Xu, Biao; Jing, Ma; Zhang, Chaoqun; Li, Xiao; Chen, Xiufeng

doi:10.1007/s00405-018-5113-2

Cited by 6 publications

(9 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 46,138 relevant records were obtained from the initial search and 6,468 records were identified from updated search, and after screening, 51 systematic reviews (Liu and Dong, 2021;Zhang et al, 2004;Zhao et al, 2004;Hao, 2005;Hao et al, 2005;Liu et al, 2005;Chen et al, 2007;Guo et al, 2010;Liu et al, 2012;Ding et al, 2013;Lu et al, 2013;Wang et al, 2013;Xiong et al, 2013;Zhang and Wei, 2014;Zhao, 2014;Zhao et al, 2014;Wu et al, 2015;Han, 2016;Li et al, 2016;Liu et al, 2016;Zhang, 2016;Wang et al, 2017;Yan and Gao, 2017;Yue et al, 2017;Jin et al, 2018;Xiong et al, 2019;Ang et al, 2020;Yang et al, 2020a;Yu et al, 2020a;Yang et al, 2020b;Yu et al, 2020b;Fan et al, 2020;Gao et al, 2020;He, 2020;Jin et al, 20201992;Liu et al, 2020;Pang et al, 2020;Qi et al, 2020;Sun et al, 2020;Wu et al, 2020;Xiong et al, 2020;Yan et al, 2020;Ze...…”

Section: Results Of the Searching And Screeningmentioning

confidence: 99%

“…The results of the AMSTAR2 evaluation showed that of the 51 systematic reviews, three (6.52%) were of high quality (Wang S. et al, 2020;Zeng et al, 2020;Luo et al, 2021), 22 (47.83%) were of moderate quality (Zhang et al, 2004;Zhao et al, 2004;Hao, 2005;Hao et al, 2005;Liu et al, 2005;Zhao, 2014;Zhao et al, 2014;Wu et al, 2015;Wang et al, 2017;Yan and Gao, 2017;Yue et al, 2017;Jin et al, 2018;Xiong et al, 2019;Yu et al, 2020a;Yang Z. et al, 2020;Fan et al, 2020;Gao et al, 2020;Pang et al, 2020;Sun et al, 2020;Xiong et al, 2020), ten (21.74%) were of low quality Chen et al, 2007;Guo et al, 2010;Liu et al, 2012;Han, 2016;Li et al, 2016;Ang et al, 2020;Liu et al, 2020;Qi et al, 2020;Wu et al, 2020), and 11 (23.91%) were of very low quality (Liu and Dong, 2021;Zhao et al, 2004;Lu et al, 2013;Liu et al, 2016;Zhang and Wei, 2014;Xiong et al, 2013;Wang et al, 2013;Ding et al, 2013;Yan et al, 2020;…”

Section: Results Of Amstar2 Quality Assessmentmentioning

confidence: 99%

“…Among the lower-quality SRs, COVID-19 was also the most frequent disease (n = 4, 21.05%) (Ang et al, 2020;Liu et al, 2020;Qi et al, 2020;Wu et al, 2020), followed by SARS (n = 3, 37.50%) Chen et al, 2007;Liu et al, 2012), H1N1 (n = 1, 50.00%) (Li et al, 2016), tuberculosis (n = 1, 25.00%) (Guo et al, 2010) and bacillary dysentery (n = 1.50.00%) (Han, 2016). The highest number of very low-grade SRs reported on HFMD (n = 7, 63.64%) (Ding et al, 2013;Wang et al, 2013;Xiong et al, 2013;Zhang and Wei, 2014;He, 2020;Yan et al, 2020), followed by herpangina (n = 2, 100.00%) (Lu et al, 2013;Liu et al, 2016), COVID-19 (n = 1, 5.26%) (Liu and Dong, 2021), and mumps (n = 1, 33.33%) (Zhang, 2016). The summary of AMSTAR 2 assessment is shown in Figure 2.…”

Section: Results Of Amstar2 Quality Assessmentmentioning

confidence: 99%

“…The number of RCTs included in each systematic review ranged from 2 to 45. Regarding the type of intervention in the intervention group, TCM combined with Western medicine accounted for the greatest proportion (n = 43, 84.31%) (Liu and Dong, 2021;Fan et al, 2020;Pang et al, 2020;Jin et al, 20201992;Luo et al, 2021;Sun et al, 2020;Zeng et al, 2020;Wang S. et al, 2020;Yang et al, 2020a;Ang et al, 2020;Xiong et al, 2020;Liu et al, 2020;Gao et al, 2020;Qi et al, 2020;Wu et al, 2020;Chen et al, 2007;Liu et al, 2012;Zhang et al, 2004;Hao, 2005;Hao et al, 2005;Liu et al, 2005;Zhao et al, 2004;Zhao et al, 2014;Li et al, 2016;Jin et al, 2018;Yan and Gao, 2017;Yue et al, 2017;Guo et al, 2010;Wang et al, 2017;Han, 2016;Wu et al, 2015;Zhang, 2016;Zhao, 2014;Lu et al, 2013;Liu et al, 2016;Zhang and Wei, 2014;Xiong et al, 2013;Wang et al, 2013;Ding et al, 2013;Yu et al, 2020a;Yang et al, 2020b), with two SRs (3.92%) including studies with...…”

Section: Basic Characteristics Of the Included Literaturementioning

confidence: 99%

See 3 more Smart Citations

Clinical Evidence on the Use of Chinese Herbal Medicine for Acute Infectious Diseases: An Overview of Systematic Reviews

Luo

Zhang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Acute infectious diseases constitute the most prevalent public health emergency (PHE) in China. Chinese herbal medicine (CHM) has long been used in the treatment of acute infections, but the overall evidence of its benefit and harm has not been comprehensively and systematically evaluated.Methods: We searched CBM, CNKI, Wanfang, PubMed, Cochrane Library, embase and preprint platforms to retrieve systematic reviews (SRs) on CHM for acute infectious. Participants with COVID-19, SARS, H1N1, tuberculosis, bacillary dysentery, mumps, herpangina, hand-foot-and-mouth disease (HFMD), and other acute infectious diseases were included. Interventional group consisting of patients treated with CHM combined with Western medicine or CHM alone. The AMSTAR 2 tool was used to assess the methodological quality of the retrieved studies. Information on interventions, control measures and outcomes of the included studies was extracted, and meta-analyses were qualitatively synthesized.Results: A total of 51 SRs and meta-analyses were eligible for this overview, including 19 for COVID-19, 11 for hand-foot-and-mouth disease, 8 for severe acute respiratory syndrome (SARS), 4 for tuberculosis, 3 for mumps, 2 for bacillary dysentery, 2 for H1N1 influenza and 2 for herpangina. Six systematic reviews were of high quality, all of which were on the use of CHM for COVID-19; 24 were of moderate quality; 10 were of low quality; and 11 were of very low quality. CHM appeared to have potential benefits in improving clinical symptoms and signs for most infections with an acceptable safety profile, and the clinical evidence of the benefits of CHM for acute respiratory infections such as COVID-19, SARS and H1N1 seems more sufficient than that for other acute infections.Conclusion: Overall, CHM, both decoction and Chinese patent medicine, used alone or in combination with conventional medicine may offer potential benefits to relieving symptoms of people with acute respiratory infections. Full reporting of disease typing, staging, and severity, and intervention details is further required for a better evidence translation to the responses for PHE. Future CHM research should focus mainly on the specific aspects of respiratory infections such as its single use for mild infections, and the adjunct administration for sever infections, and individual CHM prescriptions for well-selected outcomes should be prioritized.

show abstract

Section: Results Of the Searching And Screeningmentioning

confidence: 99%

Section: Results Of Amstar2 Quality Assessmentmentioning

confidence: 99%

Section: Results Of Amstar2 Quality Assessmentmentioning

confidence: 99%

Section: Basic Characteristics Of the Included Literaturementioning

confidence: 99%

See 2 more Smart Citations

Clinical Evidence on the Use of Chinese Herbal Medicine for Acute Infectious Diseases: An Overview of Systematic Reviews

Luo

Zhang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Improvement: symptoms and signs improved at the end of treatment, SCR decreased by 5%–15%, and the patient's symptom score decreased by 30–89%. Ineffective: symptoms and signs were still obvious or even aggravated after the end of treatment, SCR decreased by less than 5%, and the patient's symptom score decreased by less than 30% [ 15 ]. Total effective rate = (number of patients with markedly effective + number of patients with improvement)/total number of cases ∗ 100%.…”

Section: Methodsmentioning

confidence: 99%

The Efficacy of Hydroxychloroquine Combined with Huangqi Tablets in the Treatment of Diabetic Nephropathy

Chen

Sheng

Kong

2021

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Objective. This study aimed to analyze the effect of hydroxychloroquine combined with Huangqi tablets in the treatment of diabetic nephropathy (DN). Methods. Eighty patients with DN were enrolled and divided into two groups by a random number table. 27 patients received routine treatment + hydroxychloroquine (group A), while 27 patients received routine treatment + hydroxychloroquine + Huangqi tablets (group B) and 26 patients received routine treatment (group C). Results. FPG, 2h PG, and HbA1c levels as well as TC and TG levels were lower in group B than in groups A and C at the end of 3 months of treatment and were lower in group A than in group C ( P < 0.05). SCR, BUN, and 24-hour urine protein were reduced in group B after therapy, whereas eGFR was increased and the difference between groups A and C was significant ( P = 0.05 ). After treatment, VEGF, IGF-1, and TGF-1 levels were lower in group B than in groups A and C and in group A than in group C ( P = 0.05 ). Total symptom scores at 2, 4, and 6 months after treatment was lower in group B than in groups A and C, and they were lower in group A than in group C at all time points ( P < 0.05). The total effective rates of treatment in groups A, B, and C were 66.67%, 88.89%, and 38.46% ( P < 0.05). The incidence of adverse reactions in groups A, B, and C was 37.04%, 25.93%, and 11.54% ( P > 0.05). Conclusion. Hydroxychloroquine combined with Huangqi tablets in the treatment of DN showed the best efficacy, with better control of blood glucose and lipids, which can more effectively delay the progression of renal lesions and effectively inhibit the expression of VEGF, IGF, and TGF-β1 in tethered cells with high safety.

show abstract

Chinese herbal medicine combined with Western medicine for Mycoplasma pneumoniae pneumonia in children: An overview of systematic reviews

Zhang,

Cui

et al. 2024

Journal of Traditional Chinese Medical Sciences

View full text Add to dashboard Cite

Meta-analysis of Chinese medicine in the treatment of adenoidal hypertrophy in children

Cited by 6 publications

References 2 publications

Clinical Evidence on the Use of Chinese Herbal Medicine for Acute Infectious Diseases: An Overview of Systematic Reviews

Clinical Evidence on the Use of Chinese Herbal Medicine for Acute Infectious Diseases: An Overview of Systematic Reviews

The Efficacy of Hydroxychloroquine Combined with Huangqi Tablets in the Treatment of Diabetic Nephropathy

Chinese herbal medicine combined with Western medicine for Mycoplasma pneumoniae pneumonia in children: An overview of systematic reviews

Contact Info

Product

Resources

About